From the Department of Molecular
Pharmacology, Stanford University School of Medicine, Stanford,
California 94305 and the § Medical Research Council
Protein Phosphorylation Unit, School of Life Sciences, Department of
Biochemistry, Wellcome Trust Building, MSI/WTB Complex, University of
Dundee, Dundee DD1 5EH , Scotland, United Kingdom
Received for publication, September 6, 2002, and in revised form, November 12, 2002
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Ser/Thr phosphorylation of insulin
receptor substrate-1 (IRS-1) is a negative regulator of insulin
signaling. One potential mechanism for this is that Ser/Thr
phosphorylation decreases the ability of IRS-1 to be
tyrosine-phosphorylated by the insulin receptor. An additional
mechanism for modulating insulin signaling is via the down-regulation
of IRS-1 protein levels. Insulin-induced degradation of IRS-1 has been
well documented, both in cells as well as in patients with diabetes.
Ser/Thr phosphorylation of IRS-1 correlates with IRS-1 degradation, yet
the details of how this occurs are still unknown. In the present study
we have examined the potential role of different signaling cascades in
the insulin-induced degradation of IRS-1. First, we found that
inhibitors of the phosphatidylinositol 3-kinase and mammalian target of
rapamycin block the degradation. Second, knockout cells lacking one of
the key effectors of this cascade, the
phosphoinositide-dependent kinase-1, were found to be
deficient in the insulin-stimulated degradation of IRS-1. Conversely, overexpression of this enzyme potentiated insulin-stimulated
IRS-1 degradation. Third, concurrent with the decrease in IRS-1
degradation, the inhibitors of the phosphatidylinositol 3-kinase and
mammalian target of rapamycin also blocked the insulin-stimulated
increase in Ser312 phosphorylation. Most important,
an IRS-1 mutant in which Ser312 was changed to alanine was
found to be resistant to insulin-stimulated IRS-1 degradation. Finally,
an inhibitor of c-Jun N-terminal kinase, SP600125, at 10 µM did not block IRS-1 degradation and IRS-1
Ser312 phosphorylation yet completely blocked
insulin-stimulated c-Jun phosphorylation. Further, insulin-stimulated
c-Jun phosphorylation was not blocked by inhibitors of the
phosphatidylinositol 3-kinase and mammalian target of rapamycin,
indicating that c-Jun N-terminal kinase is unlikely to be the kinase
phosphorylating IRS-1 Ser312 in response to insulin. In
summary, our results indicate that the insulin-stimulated degradation
of IRS-1 via the phosphatidylinositol 3-kinase pathway is in part
dependent upon the Ser312 phosphorylation of
IRS-1.
The first step in insulin action is ligand stimulation of
the insulin receptor tyrosine kinase. A number of endogenous
substrates, including insulin receptor substrates
(IRS)1 1-4 (1-4) are
phosphorylated on tyrosine residues. Tyrosine-phosphorylated IRS-1 and
IRS-2 serve as the major docking proteins for Src homology 2 domain
containing proteins (5, 6). Association of the p85 regulatory subunit
of phosphatidylinositol (PI) 3-kinase with tyrosine-phosphorylated
IRS-1/2 results in the membrane localization and activation of the p110
catalytic subunit of PI 3-kinase, leading to the generation of
phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol
3,4-bisphosphate. These lipid products induce the activation of a
number of signaling kinases including the Ser/Thr kinase Akt (7, 8),
which is phosphorylated and activated by the upstream PDK1 kinase (9).
Activation of Akt and its downstream signals have been shown to play a
critical role in mediating the metabolic actions of insulin such as
GLUT4 translocation and glucose transport (10-13), glycogen synthesis kinase 3 serine phosphorylation and glycogen synthesis (14), phosphodiesterase serine phosphorylation and anti-lipolysis (15-17), and mTOR activation and protein synthesis (18-21). However, other effects of insulin, for example its mitogenic actions, are mediated by
association of Grb2 with tyrosine-phosphorylated Shc and IRS-1/2, which
results in the activation of the mitogen-activated protein kinase
signaling pathway (5, 6). In addition, other signal cascades stimulated
by insulin may also participate in these responses (22).
Some of the same signaling molecules that are involved in the metabolic
and mitogenic actions of insulin have also been proposed to play a role
in both the feedback inhibition of the insulin signal and cellular
insulin resistance (23-25). It has been proposed that hyper-Ser/Thr
phosphorylation of IRS proteins plays a key role in the uncoupling of
the insulin signal. Hyperphosphorylation of IRS-1 on Ser/Thr residues
has been shown in both cultured cells and in vivo to be
associated with an insulin-resistant state (26, 27). Densensitization
of the insulin signal via IRS-1 Ser/Thr phosphorylation can result from
counterregulatory hormone activation, proinflammatory cytokine
production/cellular stress, or inhibition of protein phosphatases 1 and
2A (26, 28-31). Several specific phosphorylation sites have been
identified as targets of these counter regulatory hormones and their
signaling cascades. Activation of the mitogen-activated protein kinase
signaling pathway has been shown to result in an increase in the
phosphorylation of Ser616 of IRS-1 (32,
33),2 whereas activation of
the JNK has been shown to result in the stimulation of
Ser3122 phosphorylation of IRS-1 (34). Other Ser/Thr
phosphorylation sites have also been identified in the IRS-1 molecule
(35, 36). There are several potential mechanisms by which hyper-Ser/Thr phosphorylation of IRS proteins could block the insulin signal. These
include uncoupling of IRS proteins from cytoskeletal/membrane components, which causes translocation of IRS-1 to the cytosol (37,
38); inhibition of the insulin receptor-IRS interaction (30, 39);
inhibition of the association of Src homology 2 domain-containing
proteins to IRS proteins, such as PI 3-kinase (28, 32, 33); and
inhibition of the insulin receptor phosphotransferase activity
(26).
An additional mechanism of modulating the insulin signal transduction
pathway is via the degradation of key components in this cascade.
Degradation of IRS-1 has been shown in a number of cell lines and
primary cells treated with chronic insulin (40-47). In addition, low
IRS-1 protein levels are observed in animal models of insulin
resistance and in adipocytes isolated from type 2 diabetic subjects but
not type 1 diabetic subjects (48, 49). The molecular mechanism of IRS-1
degradation has been the focus of numerous recent studies. Selective
inhibitors of PI 3-kinase and mTOR have been shown in some, but not
all, systems to inhibit insulin-stimulated IRS-1 degradation,
consistent with the hypothesis that the degradation of IRS-1 is
initiated via the PI 3-kinase/Akt/mTOR signaling pathway (41-43, 50).
However, because these inhibitors may have unknown additional effects,
it is important to confirm these results by other approaches. Thus, an
important finding was that expression of a constitutively active,
membrane-targeted PI 3-kinase, p110CAAX, induces IRS-1
degradation and hyper-Ser/Thr phosphorylation (44, 46, 51). These
results therefore argue that the overexpression of the PI 3-kinase
cascade leads to the degradation of IRS-1. However, no studies to date
have reported on the ability of insulin to induce IRS-1 degradation in
cells lacking the PI 3-kinase or other downstream components of this cascade.
After activation of the PI 3-kinase cascade, IRS-1 appears to be
degraded via the proteasome pathway. Evidence in favor of this model
includes the finding that specific inhibitors of the 26 S proteasome
block IRS-1 degradation but not Ser/Thr phosphorylation (42, 44, 46,
47, 52). More recently, a temperature-sensitive mutant of
ubiquitin-activating enzyme E1 was shown to completely block
insulin-stimulated IRS-1 degradation (47). In addition, several studies
have reported that insulin stimulates the ubiquitination of IRS-1 (47,
52).
Ser/Thr phosphorylation of IRS-1 correlates with IRS-1 degradation,
suggesting that the phosphorylation triggers the subsequent degradation. The identification of regulatory phosphorylation sites
required for IRS-1 degradation and the kinase that phosphorylates these
sites is critical to the further understanding of the mechanism of
IRS-1 degradation. The present studies were designed to examine the
role of phosphorylation at specific Ser residues in IRS-1 degradation
and the kinase cascade responsible for initiating the degradation
process. Because both human Ser312 phosphorylation and
Ser616 phosphorylation correlate with desensitization, we
have investigated whether phosphorylation at these sites can modulate
IRS-1 degradation. We have found that inhibition of IRS-1 degradation
by inhibitors of the PI 3-kinase/Akt/mTOR pathway correlates with
inhibition of IRS-1 Ser312 phosphorylation. Moreover the
insulin-stimulated degradation of a mutant IRS-1 in which
Ser312 was replaced with Ala was decreased compared with
the wt IRS-1. In contrast, a mutant IRS-1 in which Ser616
was changed to Ala exhibited insulin-induced degradation comparable with the wt IRS-1. Insulin-stimulated IRS-1 degradation and
Ser312 phosphorylation was partially blocked with a JNK
small molecule inhibitor. However, subsequent studies showed that the
insulin-stimulated phosphorylation of Ser312 was unlikely
to be due to JNK because other inhibitors (like LY294002) could also
block this phosphorylation without inhibiting JNK. These results
indicate that phosphorylation at Ser312 is necessary for
insulin-stimulated degradation and suggests that phosphorylation at
Ser312 has a dual mechanism of modulating insulin action:
uncoupling the interaction of IRS-1 with the insulin receptor as well
as the targeting of IRS-1 to the degradation pathway.
Materials--
Polyclonal antibodies to IRS-1,
Ser(P)307/312 IRS-1, IRS-2, and PI 3-kinase (p85) were from
Upstate Biotechnology (Lake Placid, NY). Polyclonal
anti-Ser(P)616 IRS-1 antibody was from
BIOSOURCE (Camarillo, CA). Monoclonal anti-Ser(P)63 c-Jun antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal
anti-Thr(P)202/Tyr204 ERK1/2 was from Cell
Signaling (Beverly, MA). Monoclonal anti-Akt1 antibody was from
Transduction Laboratories (San Diego, CA). Monoclonal anti-IRS-1
antibody (1D6) was used as shown (28). Polyclonal anti-ERK1/2 antibody
(DC3) was a gift from James E. Ferrell, Jr. (Stanford University,
Stanford, CA). Cloning enzymes and competent DH5 Plasmid Construction and Mutagenesis--
C terminus
epitope-tagged human IRS-1 was subcloned from pFastBac (53) using
EcoRI, XbaI, and EcoRV restriction
enzymes and ligated into EcoRI- and XbaI-digested
pcDNA3.1 (+) zeocin. Ser616 or Ser312 in
human IRS-1 was mutated to Ala (S616A or S312A, respectively) with the
QuikChange XL mutagenesis kit using the sense primer 5'-TACATGCCCATGGCCCCAGGGGTGG-3' and antisense primer
5'-CCACCCCTGGGGCCATGGGCATGTA-3' or sense primer
5'-CACGCACTGAGGCCATCACCGCC-3' and antisense primer 5'-GGCGGTGATGGCCTCAGTGCGTG-3', respectively, according to the manufacturer's instructions. The plasmids and mutant sites were verified by restriction digestion and sequencing. Wild type, S616A, and
S312A human IRS-1 were subcloned from pcDNA3.1 (+) zeocin into the
retroviral vector pWZL blasticidine by digestion with BglII,
treatment with Klenow to create blunt ends, and then digestion with
EcoRI. The vector pWZL blasticidine was prepared for
ligation by digestion with XbaI, followed by treatment with
Klenow to create blunt ends and then digestion with EcoRI
and CIAP treatment. N-terminal Myc-tagged human PDK1 (54) was subcloned
into the vector pWZL hygromycin.
Generation of Stable Cell Lines Expressing the Wild Type and
Mutant IRS-1 and PDK1--
H4IIErat hepatoma cells were infected with
pWZL-expressing IRS-1 or PDK1 constructs as described (55), with slight
modifications. Briefly, 85% confluent Phoenix packaging cells were
transfected using FuGENE 6 (Roche Molecular Biochemicals) or
LipofectAMINE (Invitrogen) according to the manufacturer's
instructions. 24 h post-transfection, fresh medium was added and
allowed to incubate at 37 °C for 24 h to generate viral
supernatant. 50-60% confluent H4IIE cells were incubated with viral
supernatant for 24 h at 37 °C. Stable cell pools expressing
IRS-1 were generated by selection for 48 h with 5 µg/ml
blasticidine HCl and then maintained in 1 µg/ml blasticidine HCl.
Stable cell pools expressing PDK1 were selected with 500 µg/ml hygromycin.
Cell Culture and Treatments--
H4IIE cells were maintained in
Dulbecco's modified Eagle's medium containing 5% fetal bovine serum,
5% newborn calf serum at 37 °C and 5% CO2 and then
serum deprived for 10-18 h in Dulbecco's modified Eagle's medium
containing 0.2% bovine serum albumin. The cells were pretreated with
various inhibitors or Me2SO for 30 min prior to insulin
stimulation. Insulin or 0.01 N HCl was added at the time of
serum deprivation as described in the figure legends. Mouse embryonic
stem (ES) cells lacking PDK1 and control ES cells were cultured as
previously described (56, 57). ES cells were serum deprived for 3 h in Dulbecco's modified Eagle's medium containing 0.5% bovine serum
albumin and 20 mM Hepes prior to insulin stimulation as
described in the figure legends.
Immunoprecipitation and Immunoblotting--
H4IIE cells were
lysed by shaking on ice for 20 min with 50 mM Hepes, pH
7.5, 150 mM NaCl, 1% Nonidet P-40, 1 mM
NA3VO4, 100 nM okadaic acid, and
1× protease inhibitor set I mixture (Calbiochem). Cellular debris was
removed by centrifugation at 15,000 rpm for 15 min at 4 °C. The
protein content was determined by the BCA assay. Approximately 20-30
and 200-300 µg of protein were used for analyses of total cell
lysates and immunoprecipitations, respectively. Immunoprecipitations
were performed with 30 µl of anti-FLAG agarose at 4 °C for 3 h. Immunoprecipitated IRS-1 proteins were washed with 20 mM
Tris, pH 7.4, 200 mM NaCl, 0.1% Triton X-100; then with 50 mM Tris, pH 7.4, 500 mM NaCl; then with 50 mM Tris, pH 7.4, 150 mM NaCl; and then with 20 mM Tris, pH 7.4, 200 mM NaCl. Agarose beads
were resuspended in 1× sample buffer (58 mM Tris, pH 6.8, 1% SDS, 40% glycerol, and 0.1 M dithiothreitol). H4PDK1 and ES cells were lysed on ice with buffer B (50 mM Tris,
pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM EDTA, 1 mM dithiothreitol, 1 mM
benzamidine, 1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 10 µg/ml aprotinin, 30 mM
NaPPi, 1 mM NA3VO4, and
100 nM okadaic acid). Cellular debris was removed by
centrifugation at 15,000 rpm for 15 min at 4 °C. The
immunoprecipitations were performed with 2 µl of anti-IRS-1 antibody
(ID6) at 4 °C for 3 h, followed by collection on protein
G-Sepharose. Immunoprecipitated IRS-1 proteins were washed three times
with buffer B. Sepharose beads were resuspended in 1× sample buffer.
The samples were boiled for 5 min and subjected to SDS-PAGE using 6%,
7.5%, or 10% Tris-glycine gels, then transferred to nitrocellulose
(Schleicher & Schüll). The membranes were incubated with various
antibodies overnight at 4 °C. Following washing, incubation with
horseradish peroxidase-conjugated secondary antibody (1:5000) for
1 h at room temperature, and washing, detection was carried out
with enhanced chemiluminescent substrate.
Analysis of c-Jun Phosphorylation--
H4IIE cells in 6-well
plates were lysed with 1× sample buffer. The samples were boiled for 5 min, and cellular debris was pelleted by centrifugation at 15,000 rpm
for 5 min at room temperature. 30 µl were used for SDS-PAGE on 10%
Tris-glycine gels and processed as described above.
Statistical Analysis--
Chemiluminescent signals were directly
quantitated using the Kodak 440CF Image Station and Kodak 1D version
3.5.3 software or by scanning densitometry and image analysis using NIH
Image software (rsb.info.nih.gov/nih-image/). The absolute integration value of the immunoreactive bands minus background was determined. The
statistical significance was determined by Students t test ( Insulin Stimulates IRS-1 Degradation--
Insulin-stimulated
degradation of IRS-1 has been reported in a number of cellular models
of insulin resistance (42, 46, 47, 58). To determine whether IRS-1
protein levels are regulated by insulin in the highly responsive rat
hepatomas H4IIE cells (59), cells stably expressing FLAG-tagged wild
type human IRS-1 (H4 wt IRS-1) were stimulated with various
concentrations of insulin for 18 h. The cell lysates were analyzed
by SDS-PAGE followed by transfer to nitrocellulose and immunoblotting
with anti-IRS-1 antibodies. A dose-dependent decrease in
IRS-1 protein levels was detected with a 60 ± 4% decrease at 10 nM insulin (Fig.
1A). A control blot of the p85
subunit of PI 3-kinase in total cell lysates showed no decrease under
the same conditions (Fig. 1A). To confirm the role of
intracellular proteolysis in this insulin-stimulated IRS-1 degradation,
H4 wt IRS-1 cells were pretreated with or without MG132 and
lactacystin, specific inhibitors of the 26 S proteasome. Consistent
with other cellular models of insulin-stimulated IRS-1 degradation (42,
46, 47, 58), MG132 and lactacystin completely blocked
insulin-stimulated degradation (Fig. 1B, lanes 5 and 7 versus lane 3). The ability of MG132 alone
to stimulate a shift in the molecular weight of the IRS-1 (Fig.
1B) indicates that it is likely activating the
stress-activated kinases in these cells. The lack of an IRS-1 band in
the anti-FLAG immunoprecipitates from the parental H4IIE cells Fig.
1B, lane 1) verifies that the band being detected
is the expressed human IRS-1.
Modulation of Insulin-stimulated IRS-1 Degradation by the PI3
Kinase/Akt/mTOR Pathway--
To investigate the
signaling pathways mediating insulin-stimulated IRS-1 degradation in
the H4IIE cells, H4 wt IRS-1 cells were pretreated with various
inhibitors for 30 min and then stimulated with 10 nM
insulin for 18 h. The cell lysates were analyzed by SDS-PAGE
followed by transfer to nitrocellulose and immunoblotting. In the
absence of any inhibitor, a 60 ± 4% (n = 4)
reduction in IRS-1 protein levels was detected with insulin
stimulation. In the presence of the PI 3-kinase inhibitor LY294002, no
IRS-1 degradation occurred (Fig. 2,
A and C). Treatment
of the H4 cells with this drug actually increased the IRS-1 levels,
suggesting that even the basal turnover of IRS-1 was being inhibited.
To determine whether downstream members of this pathway are involved,
rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), was
tested for its effect. Rapamycin also completely blocked
insulin-stimulated IRS-1 degradation (116 ± 2% of nontreated,
n = 4). Controls verified that at the concentrations
used, rapamycin and LY294002 completely inhibited the
insulin-stimulated mobility shift in p70 S6 kinase (Fig.
2A). In contrast to these results, the MEK1/2 inhibitor UO126 did not inhibit (p = 0.48, n = 3)
insulin-stimulated IRS-1 degradation (Fig. 2, A and
C). As a control, the effect of pretreatment with UO126 on
insulin-stimulated ERK1/2 activation was assessed. Insulin stimulated a
~18-fold increase in ERK1/2 (Thr202/Tyr204)
phosphorylation that was completely blocked by pretreatment with UO126
(Fig. 2B), whereas no inhibition of the insulin-stimulated shift in p70 S6 kinase was observed.
To assess what effects these inhibitors had on the specific
phosphorylation sites in IRS-1, the IRS-1 from these cells was probed
with anti-Ser(P)312 and anti-Ser(P)616.
Intriguingly, the insulin-stimulated increase in Ser312
phosphorylation was reduced 90 ± 2 and 78 ± 2% by LY294002
and rapamycin pretreatment, respectively (Fig. 2,
A and D). On the other hand, the MEK inhibitor,
UO126, only partially reduced Ser312 phosphorylation
(48 ± 1%). In contrast, the MEK inhibitor had a greater ability
to inhibit Ser616 phosphorylation (66 ± 17%). This
is consistent with the prior data that identified this site as a
mitogen-activated protein kinase-regulated Ser phosphorylation site
(32, 33). In contrast to the results on Ser312, the
insulin-stimulated increase in Ser616 phosphorylation
(~5-fold) was not significantly reduced by LY294002 and rapamycin
pretreatment (74 ± 35 and 75 ± 16% of nontreated, respectively) (Fig. 2D).
Because chemical inhibitors may act on undefined targets in cells in
addition to their intended targets, we sought to further test the role
of the PI 3-kinase cascade in the insulin-stimulated degradation of
IRS-1. As a first step, we overexpressed PDK1 in the H4IIE cells. As
expected, these cells showed an increase in response to the
insulin-stimulated phosphorylation of Akt on Thr308, the
PDK1 phosphorylation site (60, 61). More importantly for the purposes
of these studies, the H4IIE cells overexpressing PDK1 showed an
increased sensitivity in the insulin-stimulated degradation of IRS-1
(Fig. 3A). To further test the
role of this pathway in the insulin-stimulated degradation of IRS-1, we
then examined the ability of insulin (and insulin-like growth factor-I) to stimulate IRS-1 degradation in ES cells lacking PDK1 (57). In
comparison with the parental PDK1 cells, insulin and insulin-like growth factor I stimulated a much lower amount of IRS-1
degradation in these cells (Fig. 3B).
The Role of Ser616 in Insulin-stimulated IRS-1
Degradation--
The above results strongly support the role of
the PI 3-kinase/Akt/mTOR pathway in the insulin-stimulated
degradation of IRS-1. To determine the role of specific Ser
phosphorylation sites in the insulin-stimulated degradation of IRS-1,
we then assessed the ability of insulin to stimulate the degradation of
various mutant IRS-1 molecules. As noted above, insulin greatly
stimulated the phosphorylation of Ser616. The human IRS-1
Ser616 was mutated to Ala (S616A), and stable H4IIE cells
expressing S616A IRS-1 (H4 S616A IRS-1) were generated as described
under "Experimental Procedures." H4IIE cells stably expressing
either the wt IRS-1 or S616A IRS-1 were stimulated with 10 nM insulin for 18 h. Anti-FLAG immunoprecipitates and
cell lysates were analyzed by SDS-PAGE followed by transfer to
nitrocellulose and immunoblotting. Both wild type IRS-1 and the S616A
mutant were comparably degraded after stimulation with insulin (62 ± 4 and 49 ± 9% of nontreated, respectively) (Fig.
4). The specificity of the
anti-Ser(P)616 antibody was confirmed by the finding that
the IRS-1 S616A mutant protein only weakly reacted with this antibody
compared with wild type IRS-1 (Fig. 4A). These results
suggest that phosphorylation at Ser616 does not play a
major role in insulin-stimulated IRS-1 degradation.
The Role of Ser312 in Insulin-stimulated IRS-1
Degradation--
In addition to Ser616, insulin
also stimulates the phosphorylation of IRS Ser312. However,
in contrast to the insulin-stimulated phosphorylation of IRS-1 on
Ser616, IRS-1 Ser312 phosphorylation was
inhibited by the same agents (LY294002 and rapamycin) that inhibited
the insulin-stimulated IRS-1 degradation. To directly test the
potential role of Ser312 phosphorylation in
insulin-stimulated IRS-1 degradation, this Ser was mutated to Ala, and
H4IIE cells stably overexpressing S312A IRS-1 (H4 S312A IRS-1) were
generated as described under "Experimental Procedures." H4IIE cells
stably expressing either wt or the mutant S312A IRS-1 were stimulated
with 10 nM insulin for 18 h. Anti-FLAG
immunoprecipitates and cell lysates were analyzed by SDS-PAGE followed
by transfer to nitrocellulose and immunoblotting. 70 ± 2 and
68 ± 2% (n = 3) reductions in wt IRS-1 protein
levels were detected in anti-FLAG immunoprecipitates and total cell
lysates, respectively. In contrast, the degradation of S312A IRS-1 was greatly reduced, whether the IRS-1 was detected in anti-FLAG
immunoprecipitates with anti-IRS-1 immunoblotting or in total cell
lysates with anti-FLAG immunoblotting (Fig. 5,
A and C). The
specificity of the anti-Ser(P)312 antibody used in these
studies was confirmed by the finding that the IRS-1 S312A mutant
protein only weakly reacted with this antibody compared with wild type
IRS-1 (Fig. 5A).
To test the possibility that there is a general defect in the
insulin-stimulated protein degradation in the H4 S312A IRS-1-expressing cells, H4 wt and S312A IRS-1 cells were stimulated with 10 nM insulin for 18 h, and the extent of degradation of
the endogenous IRS-2 was measured. No difference was detected in the
insulin-stimulated degradation of IRS-2 in H4 wt and S312A IRS-1 cells
(Fig. 5B), indicating that there was no general decrease in
the ability of insulin to stimulate IRS degradation in these cells
expressing the mutant IRS-1.
Further studies were performed on both the dose and time dependence of
wt and S312A mutant IRS-1 degradation. As above, controls were
performed for total cellular protein by measuring the total levels of
p85 in all the lysates. Insulin stimulated a dose-dependent decrease in wt IRS-1 levels with an ED50 value of ~1
nM. In contrast, the S312A IRS-1 required ~100 times as
much insulin to induce a comparable amount of degradation
(ED50 = ~100 nM) (Fig.
6A). The time dependence of
the insulin-stimulated decrease in IRS-1 levels was also impaired in
the S312A mutant as compared with the wt IRS-1. The IRS-1 degradation
shifted from having a t1/2 value of ~4 h for the
wt IRS-1 to a t1/2 value of ~14 h with the mutant
IRS-1 (Fig. 6B).
Degradation of IRS-1 Inhibits Insulin Signaling--
To test
whether IRS-1 degradation inhibits insulin action, H4 wt IRS-1 cells
were stimulated with or without insulin for 15 min, after pretreatment
with 5 nM insulin for 24 h to induce IRS-1 degradation. The cell lysates were analyzed by SDS-PAGE followed by
transfer to nitrocellulose and immunoblotting. ERK1/2
in vivo activation was assessed by immunoblotting with an
anti-phospho-ERK1/2 antibody. No differences were detected in ERK1/2
protein levels in H4 wt IRS-1 cells pretreated with 5 nM
insulin for 24 h (Fig. 7A). However, a 65 ± 4%
(n = 3) reduction in insulin-stimulated ERK1/2
activation was detected in H4 wt IRS-1 cells pretreated with 5 nM insulin for 24 h (Fig. 7A). To determine
whether insulin-stimulated ERK1/2 activation was impaired to a similar
extent in cells expressing the S312A mutant that is resistant to
insulin-induced degradation, H4IIE cells stably expressing either wt or
the mutant S312A IRS-1 were pretreated with 5 nM insulin
for 24 h to stimulate IRS-1 degradation and then stimulated with
various doses of insulin for 15 min. ERK1/2 was activated to a greater
extent in H4IIE cells expressing the mutant S312A IRS-1 compared with
wt expressing cells (Fig. 7B). These results indicate that
S312A mutant IRS-1 that is more resistant to insulin-induced
degradation confers on these cells a greater insulin response after a
24-h insulin pretreatment than the wild type IRS-1.
Modulation of Insulin-stimulated IRS-1 Degradation by the JNK
Inhibitor SP600125--
To further characterize the signaling pathway
leading to insulin-stimulated IRS-1 degradation and Ser312
phosphorylation, H4 wt IRS-1 cells were pretreated with the JNK inhibitor SP600125 (62) for 30 min and then stimulated with 10 nM insulin for 18 h. The cell lysates were analyzed by
SDS-PAGE followed by transfer to nitrocellulose and immunoblotting. In contrast to the 61 ± 6% degradation induced by insulin in the absence of inhibitor, insulin only induced a 27 ± 11%
degradation in the presence of 25 µM SP600125 (Fig.
8, A and B). When
10 µM SP600125 was present, the ability of insulin to
stimulate IRS-1 degradation was unaffected. In these experiments,
insulin stimulated a ~7-fold increase in Ser312
phosphorylation, that was reduced by 53 ± 4% with SP600125
pretreatment at 25 µM (Fig. 8). However, pretreatment
with SP600125 at 10 µM did not block Ser312
phosphorylation induced after an 18-h treatment with insulin.
Modulation of Insulin-stimulated c-Jun Phosphorylation by the JNK
Inhibitor SP600125 and by the PI3 Kinase/Akt/mTOR
Pathway--
To correlate the ability of the various inhibitors used
to block insulin-stimulated IRS-1 degradation and inhibit JNK
activation, H4 wt IRS-1 cells were pretreated with the inhibitors for
30 min and then stimulated with 100 nM insulin for 15 min.
The cells were lysed by the addition of 1× sample buffer and analyzed
by SDS-PAGE followed by transfer to nitrocellulose and immunoblotting. JNK in vivo activity was assessed by immunoblotting with an
anti-pS63 c-Jun antibody. Insulin stimulated a ~2-fold increase in
c-Jun phosphorylation that was completely blocked by pretreatment with either 25 or 10 µM SP600125 (Fig.
9A). In contrast, pretreatment with UO126 resulted in a 25 ± 21% reduction in c-Jun
phosphorylation that was not significantly different from nontreated
cells. Thus, SP600125 appears to be a potent inhibitor of JNK. In
contrast to the complete inhibition of insulin-stimulated c-Jun
phosphorylation at even 10 µM, SP600125 treatment of
cells resulted in only a partial inhibition of insulin-stimulated IRS-1
Ser312 phosphorylation observed after 15 min (Fig.
9B). For example, at 10 µM, SP600125 caused a
42 ± 2% reduction in insulin-stimulated phosphorylation of
Ser312 (Fig. 8B). Surprisingly, SP600125 also
caused a similar level of inhibition in insulin-stimulated IRS-1
Ser616 phosphorylation (64 ± 18 and 41 ± 7%
reductions in Ser612 phosphorylation were observed at 25 and 10 µM, respectively) (Fig. 9B). To
determine whether the PI 3-kinase/Akt/mTOR pathway mediates
insulin-stimulated c-Jun phosphorylation, the cells were pretreated
with LY294002 and rapamycin prior to insulin stimulation. In contrast
to the results with the JNK inhibitor, SP600125, LY294002, and
rapamycin did not inhibit insulin-stimulated c-Jun phosphorylation (Fig. 9C).
Numerous studies have demonstrated that Ser/Thr phosphorylation of
IRS-1 inhibits insulin receptor-catalyzed IRS-1 tyrosine phosphorylation and the subsequent downstream signaling actions of
insulin (24, 25, 63). One of the specific Ser phosphorylation sites in
IRS-1 that has been proposed to negatively modulate the insulin signal
is Ser312 (numbered according to the human sequence). Prior
studies have demonstrated that IRS-1 associates with and is
phosphorylated by JNK in vitro on Ser312 (34).
Using a yeast tri-hybrid assay, it was shown that an active JNK blocked
the interaction between the insulin receptor and IRS-1, thus suggesting
that Ser312 phosphorylation may interfere with IRS-1 PTB
domain function (64). Phosphorylation of IRS-1 at Ser312
also mediates the inhibitory effect of tumor necrosis factor In the present studies we have used a recently described inhibitor of
JNK, SP600125 (62). Treatment of cells with 10 µM SP600125 completely blocked insulin-stimulated in vivo c-Jun
phosphorylation. However, even 25 µM SP600125 only
partially inhibited insulin induced Ser312 phosphorylation.
Further, inhibitors of the PI 3-kinase/Akt/mTOR pathway that block
insulin-stimulated IRS-1 degradation and Ser312
phosphorylation had no effect on insulin-stimulated in vivo
c-Jun phosphorylation. These results are most consistent with a
kinase other than JNK being responsible for the insulin-stimulated
Ser312 phosphorylation of IRS-1. In contrast to our results
in rat hepatoma cells, Lee et al. (66) recently reported
that the PI 3-kinase inhibitor LY294002 blocked insulin-stimulated JNK
activation and c-Jun phosphorylation in 32D cells overexpressing the
insulin receptor. The finding that the JNK inhibitor partially blocks Ser616 phosphorylation of IRS-1 suggests that this
inhibitor is not specific for JNK. Another recent report also concluded
that this inhibitor is not specific for JNK (68). In the original
report on this inhibitor (62), it was suggested that SP600125 may have activity toward several mitogen-activated protein kinase kinase isoforms and Akt based on in vitro screening and the partial
inhibition of phospho-p38 and ATF in Jurkat T cells. In any case, our
results indicate that JNK is unlikely to be the kinase phosphorylating IRS-1 Ser312 in response to insulin and are consistent with
the hypothesis that multiple kinases mediate IRS-1 Ser312
phosphorylation. In agreement with this hypothesis is the recent evidence that IKK2 directly phosphorylated IRS-1 Ser312
(69).
A role for the PI 3-kinase cascade in the insulin-stimulated
degradation of IRS-1 is supported by the finding that overexpression of
a constitutively active form of the p110 subunit of PI 3-kinase is
sufficient to induce IRS-1 degradation, whereas inhibition of PI
3-kinase by LY294002 inhibits insulin-stimulated IRS-1 degradation (43,
44, 46, 51). In H4IIE cells stably expressing a wt IRS-1, inhibition of
PI 3-kinase by LY294002 also completely blocked insulin-induced IRS-1
degradation. Further, inhibition of mTOR, a downstream effector of PI
3-kinase, by rapamycin also blocked insulin-stimulated IRS-1
degradation in these cells. The mechanism by which mTOR regulates the
phosphorylation and subsequent degradation of IRS-1 is not known. It is
possible that mTOR is associated with and regulates a phosphatase (70).
It is also possible that mTOR directly phosphorylates IRS-1
Ser312, although phosphorylation at this Ser residue in
IRS-1 was not previously identified (35).
The inhibitors used in the present work may act on targets in addition
to their intended enzymes. Therefore, we sought to confirm the role of
the PI 3-kinase cascade in the insulin-stimulated degradation of IRS-1.
We first overexpressed PDK1, the upstream activator of the Akt pathway.
We were able to show that overexpression of this kinase potentiated the
ability of insulin to stimulate IRS-1 degradation. Even more important,
we found that ES cells lacking PDK1 showed a dramatic decrease in the
ability of insulin and insulin-like growth factor-I to stimulate IRS-1
degradation. These results therefore further document the hypothesized
role of the PI 3-kinase cascade in the insulin-induced degradation of
IRS-1 (42-44, 46). However, these studies are not consistent with a
recent study in Chinese hamster ovary cells overexpressing the insulin
receptor in which the mTOR inhibitor rapamycin was found not to block
insulin induced IRS-1 degradation, possibly suggesting that there may
be cell-specific pathways for IRS-1. To further clarify the steps
whereby activation of the PI 3-kinase pathway leads to the degradation
of IRS-1, we have examined the role of specific IRS-1 phosphorylation
sites in this process. We found that inhibitors of the PI
3-kinase/Akt/mTOR pathway block insulin-stimulated IRS-1 degradation as
well as inhibit Ser312 phosphorylation of IRS-1. We
therefore produced an IRS-1 mutant in which Ser312 was
changed to Ala and examined the ability of insulin to stimulate the
degradation of this molecule. We found that this mutant IRS-1 was
resistant to insulin-stimulated IRS-1 degradation. In contrast, a
mutant IRS-1 in which Ser616 was changed to Ala exhibited a
comparable insulin-stimulated degradation as the wt IRS-1. We next
sought to investigate insulin action in H4IIE cells in which IRS-1 was degraded.
Our results strongly suggest a novel dual mechanism for the inhibition
of the insulin signal, whereby Ser312 phosphorylation
uncouples IRS-1 from the insulin receptor as well as regulating its
degradation. However, the finding that the IRS-1 mutant was degraded at
high concentrations of insulin during a long term stimulation suggests
that Ser312 phosphorylation is not the sole determinant for degradation.
The mechanism by which Ser312 phosphorylation promotes
degradation is not known. It is possible that Ser312
phosphorylation promotes ubiquitination of IRS-1. However, the ability
of insulin to stimulate ubiquitination of IRS-1 has not been
consistently observed (47, 58). An alternative possibility for the
mechanism by which Ser312 phosphorylation promotes
degradation is that when phosphorylated, Ser312 facilitates
the subcellular redistribution of IRS-1 from the low density microsomal
or high speed pellet fraction to the cytosol. Such a redistribution
would occur, for example, if the phosphorylation of Ser312
interferes with PTB function of the IRS-1 molecule (64). In support of
such a model is the finding that rapamycin blocks the insulin-stimulated redistribution of IRS-1 from the low density microsomal fraction/high speed pellet to the cytosol (46). In the
present studies rapamycin was also found to inhibit Ser312
phosphorylation. It is possible that these results are linked; that is,
the phosphorylation of Ser312 may participate in the
insulin-stimulated redistribution of IRS-1, which could subsequently
facilitate IRS-1 degradation.
In conclusion, we have found that inhibition of IRS-1 degradation by
inhibitors of the PI 3-kinase/Akt/mTOR pathway correlates with
inhibition of IRS-1 Ser312 phosphorylation. Direct evidence
for a participation of Ser312 phosphorylation in
insulin-stimulated IRS-1 degradation was obtained because
Ser312 mutant IRS-1 was found to be resistant to
insulin-stimulated degradation. This study therefore provides the first
evidence that a specific Ser/Thr phosphorylation site can modulate
IRS-1 degradation.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
Experimental Procedures
RESULTS
DISCUSSION
REFERENCES
Experimental Procedures
TOP
ABSTRACT
INTRODUCTION
Experimental Procedures
RESULTS
DISCUSSION
REFERENCES
cells were from
Invitrogen. Plasmid purification kits were from Qiagen. Turbo
Pfu and the QuikChange XL mutagenesis kit were from
Stratagene (La Jolla, CA). Enhanced chemiluminescence detection reagents were from Pierce. Porcine insulin, goat anti-mouse and anti-rabbit peroxidase-conjugated antibodies, monoclonal anti-FLAG, anti-FLAG-agarose, and other chemicals were from Sigma. LY294002, SP600125, rapamycin, UO126, MG132, and synthetic lactacystin were from
Calbiochem (San Diego, CA). Tris-glycine gels, NuPAGE gels, and
electrophoresis reagents were from Novex/Invitrogen.
= 0.05).
RESULTS
TOP
ABSTRACT
INTRODUCTION
Experimental Procedures
RESULTS
DISCUSSION
REFERENCES
View larger version (42K):
[in a new window]
Fig. 1.
Dose-dependent insulin-stimulated
degradation of expressed IRS-1 in H4IIE cells and the effect of
proteasome inhibitors. H4IIE cells were infected with a retrovirus
encoding a FLAG-tagged wild type human IRS-1 (H4 wt IRS-1) and
drug-selected to isolate a pool population of cells stably expressing
the construct. The cells were lysed, and the total cell lysates or
anti-FLAG immunoprecipitates were separated on 6% SDS-PAGE gels,
transferred to nitrocellulose, and blotted with anti-IRS-1 or anti-p85
antibodies. A, insulin-induced IRS-1 degradation in the H4
cells. H4 wt IRS-1 cells were treated with various doses of insulin for
18 h in serum-free medium. Representative blots from at least
three independent experiments are shown. B, proteasome
inhibitors block the insulin induced IRS-1 degradation in H4 cells.
H4IIE cells and H4 wt IRS-1 cells were pretreated with 15 µM MG132 or 5 µM lactacystin and then
stimulated with 20 nM insulin for 8 h at 37 °C.
Shown are representative blots from two independent experiments.
IB, immunoblot.
View larger version (33K):
[in a new window]
Fig. 2.
Effect of PI 3-kinase, MEK, and mTOR
inhibitors on IRS-1 degradation and phosphorylation of
Ser312 and S616. H4IIE cells
expressing FLAG-tagged wild type human IRS-1 were pretreated with or
without 30 µM LY294002 (LY), 20 nM
rapamycin (Rap), or 10 µM UO126
(UO) for 30 min at 37 °C followed by stimulation with 10 nM insulin for 18 h at 37 °C. The cells were lysed,
and the total cell lysate was separated on 6% SDS-PAGE gels,
transferred to nitrocellulose and immunoblotted. The immunoreactive
bands were directly quantitated (mean ± S.E.) from three or four
independent experiments performed in duplicate using a Kodak Work
station and Kodak 1D v.3.5.3 software. A, effect of the
inhibitors on IRS-1 degradation. Representative immunoblots
(IB) with anti-IRS-1, anti-Ser(P)312 IRS-1,
antibodies to the 70-kDa S6K, and anti-p85 antibodies are shown.
B, effect of the MEK inhibitor on ERK activation. A
representative immunoblot with
anti-Thr(P)202/Tyr204 ERK1/2 is shown from the
three independent experiments performed. C, quantitation of
the IRS-1 degradation. IRS-1 protein levels are expressed as
percentages of the nontreated controls. The results are the means ± S.E. from three independent experiments. D, IRS-1
phosphorylation. Ser312 and Ser616
phosphorylation levels were determined by blotting with the anti-Ser(P)
antibodies and expressed as percentages of the insulin-stimulated
controls. The results have been normalized for the amount of total
IRS-1 present and are the means ± S.E. of three independent
experiments. *, p < 0.05; **, p < 0.005 versus insulin-stimulated controls.
View larger version (21K):
[in a new window]
Fig. 3.
Insulin-stimulated degradation of IRS-1 in H4
cells overexpressing PDK1 and in PDK1 ( /
) ES cells.
A, effect of expression of PDK1 on IRS-1 degradation. H4IIE
cells expressing Myc-tagged PDK1 (H4 PDK1) were stimulated with 200 nM insulin for 2-24 h at 37 °C. The cells were lysed,
and the total cell lysate or anti-IRS-1 immunoprecipitates were
separated on SDS-PAGE gels, transferred to nitrocellulose, and
immunoblotted with anti-Akt1 and anti-IRS-1 antibodies, respectively.
The results have been normalized to the amount of IRS-1 present in the
control (non-insulin-treated) cells. The data shown are the means ± S.E. of three independent experiments. B, requirement for
PDK1 in the insulin-stimulated degradation of IRS-1. PDK1 (+/+) and
(
/
) ES cells were stimulated with insulin or insulin-like growth
factor I as indicated for 24 h at 37 °C. The cells were lysed,
and the total cell lysate or anti-IRS-1 immunoprecipitates were
separated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted
with anti-Akt1 and anti-IRS-1 antibodies, respectively. The upper
panel shows a representative immunoblot. The lower
panel shows the means ± S.E. of three independent
experiments.
View larger version (24K):
[in a new window]
Fig. 4.
Insulin-stimulated degradation of a S616A
mutant IRS-1. H4IIE cells were infected with a retrovirus encoding
a FLAG-tagged wild type human IRS-1 (H4 wt IRS-1) or a S616A mutant (H4
S616A IRS-1) and drug-selected to isolate a pool population of cells
stably expressing the two constructs. The cells were insulin-treated or
not and lysed, and the total cell lysate or anti-FLAG
immunoprecipitates were separated on 6% SDS-PAGE gels, transferred to
nitrocellulose, and immunoblotted (IB) with the indicated
antibodies. A representative experiment is shown (A) as well
as the means ± S.E. of three independent experiments
(B).
View larger version (27K):
[in a new window]
Fig. 5.
Insulin-stimulated degradation of a S312A
mutant IRS-1. H4IIE cells expressing FLAG-tagged wt human IRS-1
(H4 wt IRS-1) or a S312A mutant (H4 S312A IRS-1) IRS-1 were stimulated
with 10 nM insulin for 18 h at 37 °C. H4IIE, H4 wt
IRS-1, and H4 S312A IRS-1 cells were lysed, and the total cell lysates
or anti-FLAG immunoprecipitates (IP) were separated on 6%
SDS-PAGE gels, transferred to nitrocellulose, and immunoblotted
(IB) with the indicated antibodies. Immunoreactive bands
were directly quantitated using a Kodak Work station and Kodak 1D
v.3.5.3 software. A, representative immunoblots.
B, insulin-stimulated IRS-2 degradation is not impaired in
S312A expressing H4 cells. The samples from the same lysates as shown
in A were immunoblotted with anti-IRS-2 as shown.
C, quantitation of the insulin-stimulated degradation of wt
and S312A mutant IRS-1. The results shown are the means ± S.E. of
three independent experiments. *, p < 0.005 versus insulin-stimulated S312A mutant.
View larger version (38K):
[in a new window]
Fig. 6.
Dose and time dependence of the
insulin-stimulated degradation of wild type and S312A mutant
IRS-1. H4IIE cells expressing FLAG-tagged wild wt IRS-1 or S312A
mutant human IRS-1 were stimulated with indicated concentrations of
insulin and for the various times. The cells were lysed, and the total
cell lysate or anti-FLAG immunoprecipitates (IP) were
separated on 6% SDS-PAGE gels, transferred to nitrocellulose, and
immunoblotted (IB). Two independent experiments were
performed. Representative immunoblots, with anti-IRS-1 and
anti-Ser(P)312 IRS-1 from anti-FLAG immunoprecipitates or
with anti-p85 antibodies from total cell lysates, are shown.
A, dose dependence of IRS-1 degradation. B, time
course of insulin-stimulated IRS-1 degradation.
View larger version (28K):
[in a new window]
Fig. 7.
Degradation of IRS-1 inhibits insulin
signaling. H4IIE cells expressing FLAG-tagged wt human IRS-1 (H4
wt IRS-1) or a S312A mutant (H4 S312A IRS-1) IRS-1 were first
pretreated with or without 5 nM insulin for 24 h at
37 °C and then stimulated with or without insulin for 15 min at
37 °C. The Cells were lysed, and the total cell lysates were
separated on 10% SDS-PAGE gels, transferred to nitrocellulose and
immunoblotted (IB) with the indicated antibodies.
Immunoreactive bands were directly quantitated using a Kodak Work
station and Kodak 1D v.3.5.3 software. A, representative
immunoblots with pERK1/2 and total ERK1/2 antibodies from H4 wt IRS-1
cells are shown in the left panel, and the quantitation of
the results (means ± S.E.) of three independent experiments are
summarized in the right panel. B, representative
immunoblots with pERK1/2 and total ERK1/2 antibodies from H4 wt IRS-1
and H4 S312A IRS-1 cells are shown in the upper panel, and
the quantitation of the results (means ± S.E.) of three
independent experiments are summarized in the lower
panel.
View larger version (20K):
[in a new window]
Fig. 8.
Effect of a JNK inhibitor on the degradation
and phosphorylation of IRS-1. H4IIE cells expressing FLAG-tagged
wt human IRS-1 were pretreated with or without 25 or 10 µM SP600125 (SP) or 10 µM UO126
(UO) for 30 min at 37 °C followed by stimulation with 10 nM insulin for 18 h at 37 °C. The cells were lysed,
and the total cell lysates were separated on 6% SDS-PAGE gels,
transferred to nitrocellulose, and immunoblotted (IB).
Immunoreactive bands were directly quantitated in duplicate using a
Kodak Work station and Kodak 1D v.3.5.3 software. A, effect
of the inhibitor on IRS-1 degradation and phosphorylation.
Representative immunoblots with anti-IRS-1, anti-Ser(P)312
IRS-1, and anti-p85 antibodies are shown. B, quantitation of
the effects of the inhibitors on the IRS-1 levels. IRS-1 protein levels
are expressed as percentages of the nontreated control cells and are
the means ± S.E. of three independent experiments. C,
quantitation of the effects of the inhibitors on IRS-1
Ser312 phosphorylation. Ser312 phosphorylation
was quantitated, normalized for the amounts of IRS-1 present, and
expressed as a percent of the insulin-stimulated control cells. The
results shown are the means ± S.E. of three independent
experiments. *, p < 0.05; **, p < 0.005 versus insulin-stimulated controls.
View larger version (41K):
[in a new window]
Fig. 9.
Effect of JNK, PI 3-kinase, and mTOR
inhibitors on c-Jun and IRS-1 phosphorylation. H4IIE cells
expressing FLAG-tagged wt IRS-1 were pretreated with or without 25 or
10 µM SP600125 (SP), 30 µM
LY294002 (LY), 20 nM rapamycin (Rap),
or 10 µM UO126 (UO) for 30 min at 37 °C
followed by stimulation with 100 nM insulin for 15 min at
37 °C. The cells were lysed with sample buffer, and the total cell
lysates were separated on 6% SDS-PAGE gels, transferred to
nitrocellulose, and immunoblotted (IB). The immunoreactive
bands were directly quantitated in duplicate using a Kodak Work station
and Kodak 1D v.3.5.3 software. A, effect of JNK and MEK1/2
inhibitors on c-Jun phosphorylation. A representative immunoblot with
anti-Ser(P)63 c-Jun is shown in the left panel,
and the quantitation of the results (means ± S.E.) of three
independent experiments are summarized in the right panel.
B, effect on IRS-1 Ser312 and Ser616
phosphorylation. Representative immunoblots with anti-IRS-1,
anti-Ser(P)312 IRS-1 and anti-Ser(P)616 IRS-1
are shown in the left panel, and the results (means ± S.E.) of three independent experiments are summarized in the
right panel. C, effect of PI 3-kinase and mTOR
inhibitors on c-Jun phosphorylation. A representative immunoblot with
anti-Ser(P)63 c-Jun is shown in the left panel,
and the quantitation of the results (means ± S.E.) of three
independent experiments are summarized in the right
panel.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
Experimental Procedures
RESULTS
DISCUSSION
REFERENCES
on
insulin signaling, although the kinase responsible for this phosphorylation was inhibited by the MEK inhibitor PD98059 and thus is
presumably not JNK (34, 64, 65). Insulin also stimulates the
phosphorylation of IRS-1 at Ser312 by
JNK-dependent and -independent pathways (65, 66). It has also been suggested that the effect of free fatty acids on IRS-1 tyrosine phosphorylation and associated PI 3-kinase activity in rats is
mediated by activation of PKC
leading to IRS-1 Ser312
phosphorylation (67). Thus, phosphorylation of IRS-1 at
Ser312 by a variety of kinases may represent a general
mechanism of inhibiting the insulin signal pathway by uncoupling IRS-1
from the insulin receptor.
![]() |
ACKNOWLEDGEMENTS |
---|
We are grateful to Dr. James E. Ferrell, Jr., for providing the anti-ERK1/2 antibody. We also thank Dr. Robert Garofalo for helpful discussions and reviewing the manuscript.
![]() |
FOOTNOTES |
---|
* This work was supported in part by National Institutes of Health Grant DK34976 (to R. A. R.) and an American Diabetes Association mentor-based postdoctoral fellowship (to H. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Dept. of Molecular Pharmacology, Stanford University School of Medicine, Rm. 3145B, CCSR, 269 Campus Dr., Stanford, CA 94305-5174. Tel.: 650-723-5933; Fax: 650-723-2253; E-mail: rroth@stanford.edu.
Published, JBC Papers in Press, January 1, 2003, DOI 10.1074/jbc.M209153200
2 Unless otherwise specified, the sequence numbers shown correspond to the human sequence of IRS-1. Thus, Ser616 corresponds to rat Ser612 and Ser312 corresponds to rat Ser307.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: IRS, insulin receptor substrate; PI, phosphatidylinositol; PDK1, phosphoinositide-dependent kinase1; wt, wild type; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; mTOR, mammalian target of rapamycin; MEK, mitogen-activated protein kinase/extracellular signal regulated kinase kinase; ES, embryonic stem.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Lavan, B. E.,
Fantin, V. R.,
Chang, E. T.,
Lane, W. S.,
Keller, S. R.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
21403-21407 |
2. |
Lavan, B. E.,
Lane, W. S.,
and Lienhard, G. E.
(1997)
J. Biol. Chem.
272,
11439-11443 |
3. | Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., and White, M. F. (1991) Nature 352, 73-77[CrossRef][Medline] [Order article via Infotrieve] |
4. | Sun, X. J., Wang, L. M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177[CrossRef][Medline] [Order article via Infotrieve] |
5. | Ogawa, W., Matozaki, T., and Kasuga, M. (1998) Mol. Cell. Biochem. 182, 13-22[CrossRef][Medline] [Order article via Infotrieve] |
6. | White, M. F. (1998) Mol. Cell. Biochem. 182, 3-11[CrossRef][Medline] [Order article via Infotrieve] |
7. | Alessi, D. R., and Cohen, P. (1998) Curr. Opin. Genet. Dev. 8, 55-62[CrossRef][Medline] [Order article via Infotrieve] |
8. |
Lawlor, M. A.,
and Alessi, D. R.
(2001)
J. Cell Sci.
114,
2903-2910 |
9. | Alessi, D. R. (2001) Biochem. Soc. Trans. 29, 1-14[CrossRef][Medline] [Order article via Infotrieve] |
10. |
Cho, H.,
Mu, J.,
Kim, J. K.,
Thorvaldsen, J. L.,
Chu, Q.,
Crenshaw, E. B., 3rd,
Kaestner, K. H.,
Bartolomei, M. S.,
Shulman, G. I.,
and Birnbaum, M. J.
(2001)
Science
292,
1728-1731 |
11. |
Kohn, A. D.,
Summers, S. A.,
Birnbaum, M. J.,
and Roth, R. A.
(1996)
J. Biol. Chem.
271,
31372-31378 |
12. |
Kohn, A. D.,
Barthel, A.,
Kovacina, K. S.,
Boge, A.,
Wallach, B.,
Summers, S. A.,
Birnbaum, M. J.,
Scott, P. H.,
Lawrence, J. C., Jr.,
and Roth, R. A.
(1998)
J. Biol. Chem.
273,
11937-11943 |
13. |
Wang, Q.,
Somwar, R.,
Bilan, P. J.,
Liu, Z.,
Jin, J.,
Woodgett, J. R.,
and Klip, A.
(1999)
Mol. Cell. Biol.
19,
4008-4018 |
14. |
Summers, S. A.,
Kao, A. W.,
Kohn, A. D.,
Backus, G. S.,
Roth, R. A.,
Pessin, J. E.,
and Birnbaum, M. J.
(1999)
J. Biol. Chem.
274,
17934-17940 |
15. |
Kitamura, T.,
Kitamura, Y.,
Kuroda, S.,
Hino, Y.,
Ando, M.,
Kotani, K.,
Konishi, H.,
Matsuzaki, H.,
Kikkawa, U.,
Ogawa, W.,
and Kasuga, M.
(1999)
Mol. Cell. Biol.
19,
6286-6296 |
16. |
Andersen, C. B.,
Roth, R. A.,
and Conti, M.
(1998)
J. Biol. Chem.
273,
18705-18708 |
17. | Eriksson, H., Ridderstrale, M., Degerman, E., Ekholm, D., Smith, C. J., Manganiello, V. C., Belfrage, P., and Tornqvist, H. (1995) Biochim. Biophys. Acta 1266, 101-107[Medline] [Order article via Infotrieve] |
18. | Nave, B. T., Ouwens, M., Withers, D. J., Alessi, D. R., and Shepherd, P. R. (1999) Biochem. J. 344, 427-431[CrossRef][Medline] [Order article via Infotrieve] |
19. | Mendez, R., Welsh, G., Kleijn, M., Myers, M. G., White, M. F., Proud, C. G., and Rhoads, R. E. (2001) Prog. Mol. Subcell. Biol. 26, 49-93[Medline] [Order article via Infotrieve] |
20. | Proud, C. G., Wang, X., Patel, J. V., Campbell, L. E., Kleijn, M., Li, W., and Browne, G. J. (2001) Biochem. Soc. Trans. 29, 541-547[Medline] [Order article via Infotrieve] |
21. |
Scott, P. H.,
Brunn, G. J.,
Kohn, A. D.,
Roth, R. A.,
and Lawrence, J. C., Jr.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7772-7777 |
22. | Baumann, C. A., Ribon, V., Kanzaki, M., Thurmond, D. C., Mora, S., Shigematsu, S., Bickel, P. E., Pessin, J. E., and Saltiel, A. R. (2000) Nature 407, 202-207[CrossRef][Medline] [Order article via Infotrieve] |
23. |
Birnbaum, M. J.
(2001)
J. Clin. Invest.
108,
655-659 |
24. |
White, M. F.
(2002)
Am. J. Physiol.
283,
E413-E422 |
25. | Zick, Y. (2001) Trends Cell Biol. 11, 437-441[CrossRef][Medline] [Order article via Infotrieve] |
26. | Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., and Spiegelman, B. M. (1996) Science 271, 665-668[Abstract] |
27. |
Kolter, T.,
Uphues, I.,
and Eckel, J.
(1997)
Am. J. Physiol.
273,
E59-E67 |
28. |
Li, J.,
DeFea, K.,
and Roth, R. A.
(1999)
J. Biol. Chem.
274,
9351-9356 |
29. |
Mothe, I.,
and Van Obberghen, E.
(1996)
J. Biol. Chem.
271,
11222-11227 |
30. |
Paz, K.,
Hemi, R.,
LeRoith, D.,
Karasik, A.,
Elhanany, E.,
Kanety, H.,
and Zick, Y.
(1997)
J. Biol. Chem.
272,
29911-29918 |
31. | Tanti, J. F., Gremeaux, T., Van Obberghen, E., and Le Marchand-Brustel, Y. (1994) Biochem. J. 304, 17-21[Medline] [Order article via Infotrieve] |
32. |
De Fea, K.,
and Roth, R. A.
(1997)
J. Biol. Chem.
272,
31400-31406 |
33. | De Fea, K., and Roth, R. A. (1997) Biochemistry 36, 12939-12947[CrossRef][Medline] [Order article via Infotrieve] |
34. |
Aguirre, V.,
Uchida, T.,
Yenush, L.,
Davis, R.,
and White, M. F.
(2000)
J. Biol. Chem.
275,
9047-9054 |
35. |
Ozes, O. N.,
Akca, H.,
Mayo, L. D.,
Gustin, J. A.,
Maehama, T.,
Dixon, J. E.,
and Donner, D. B.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
4640-4645 |
36. |
Qiao, L. Y.,
Zhande, R.,
Jetton, T. L.,
Zhou, G.,
and Sun, X. J.
(2002)
J. Biol. Chem.
277,
26530-26539 |
37. |
Clark, S. F.,
Martin, S.,
Carozzi, A. J.,
Hill, M. M.,
and James, D. E.
(1998)
J. Cell Biol.
140,
1211-1225 |
38. |
Clark, S. F.,
Molero, J. C.,
and James, D. E.
(2000)
J. Biol. Chem.
275,
3819-3826 |
39. |
Paz, K.,
Boura-Halfon, S.,
Wyatt, L. S.,
LeRoith, D.,
and Zick, Y.
(2000)
J. Mol. Endocrinol.
24,
419-432 |
40. | Rice, K. M., Turnbow, M. A., and Garner, C. W. (1993) Biochem. Biophys. Res. Commun. 190, 961-967[CrossRef][Medline] [Order article via Infotrieve] |
41. | Berg, C. E., Lavan, B. E., and Rondinone, C. M. (2002) Biochem. Biophys. Res. Commun. 293, 1021-1027[CrossRef][Medline] [Order article via Infotrieve] |
42. |
Pederson, T. M.,
Kramer, D. L.,
and Rondinone, C. M.
(2001)
Diabetes
50,
24-31 |
43. | Hartley, D., and Cooper, G. M. (2002) J. Cell. Biochem. 85, 304-314[CrossRef][Medline] [Order article via Infotrieve] |
44. |
Haruta, T.,
Uno, T.,
Kawahara, J.,
Takano, A.,
Egawa, K.,
Sharma, P. M.,
Olefsky, J. M.,
and Kobayashi, M.
(2000)
Mol. Endocrinol.
14,
783-794 |
45. |
Rui, L.,
Fisher, T. L.,
Thomas, J.,
and White, M. F.
(2001)
J. Biol. Chem.
276,
40362-40367 |
46. |
Takano, A.,
Usui, I.,
Haruta, T.,
Kawahara, J.,
Uno, T.,
Iwata, M.,
and Kobayashi, M.
(2001)
Mol. Cell. Biol.
21,
5050-5062 |
47. |
Zhande, R.,
Mitchell, J. J.,
Wu, J.,
and Sun, X. J.
(2002)
Mol. Cell. Biol.
22,
1016-1026 |
48. |
Carvalho, E.,
Jansson, P. A.,
Axelsen, M.,
Eriksson, J. W.,
Huang, X.,
Groop, L.,
Rondinone, C.,
Sjostrom, L.,
and Smith, U.
(1999)
FASEB J.
13,
2173-2178 |
49. |
Rondinone, C. M.,
Wang, L. M.,
Lonnroth, P.,
Wesslau, C.,
Pierce, J. H.,
and Smith, U.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4171-4175 |
50. | Smith, L. K., Vlahos, C. J., Reddy, K. K., Falck, J. R., and Garner, C. W. (1995) Mol. Cell. Endocrinol. 113, 73-81[CrossRef][Medline] [Order article via Infotrieve] |
51. |
Egawa, K.,
Nakashima, N.,
Sharma, P. M.,
Maegawa, H.,
Nagai, Y.,
Kashiwagi, A.,
Kikkawa, R.,
and Olefsky, J. M.
(2000)
Endocrinology
141,
1930-1935 |
52. |
Lee, A. V.,
Gooch, J. L.,
Oesterreich, S.,
Guler, R. L.,
and Yee, D.
(2000)
Mol. Cell. Biol.
20,
1489-1496 |
53. | Greene, M. W., and Garofalo, R. S. (2002) Biochemistry 41, 7082-7091[CrossRef][Medline] [Order article via Infotrieve] |
54. | Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., Ashworth, A., and Bownes, M. (1997) Curr. Biol. 7, 776-789[Medline] [Order article via Infotrieve] |
55. |
Pear, W. S.,
Nolan, G. P.,
Scott, M. L.,
and Baltimore, D.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8392-8396 |
56. | Balendran, A., Hare, G. R., Kieloch, A., Williams, M. R., and Alessi, D. R. (2000) FEBS Lett. 484, 217-223[CrossRef][Medline] [Order article via Infotrieve] |
57. | Williams, M. R., Arthur, J. S., Balendran, A., van der Kaay, J., Poli, V., Cohen, P., and Alessi, D. R. (2000) Curr. Biol. 10, 439-448[CrossRef][Medline] [Order article via Infotrieve] |
58. | Sun, X. J., Goldberg, J. L., Qiao, L. Y., and Mitchell, J. J. (1999) Diabetes 48, 1359-1364[Abstract] |
59. |
Andreone, T. L.,
Beale, E. G.,
Bar, R. S.,
and Granner, D. K.
(1982)
J. Biol. Chem.
257,
35-38 |
60. | Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269[Medline] [Order article via Infotrieve] |
61. |
Stokoe, D.,
Stephens, L. R.,
Copeland, T.,
Gaffney, P. R.,
Reese, C. B.,
Painter, G. F.,
Holmes, A. B.,
McCormick, F.,
and Hawkins, P. T.
(1997)
Science
277,
567-570 |
62. |
Bennett, B. L.,
Sasaki, D. T.,
Murray, B. W.,
O'Leary, E. C.,
Sakata, S. T.,
Xu, W.,
Leisten, J. C.,
Motiwala, A.,
Pierce, S.,
Satoh, Y.,
Bhagwat, S. S.,
Manning, A. M.,
and Anderson, D. W.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
13681-13686 |
63. |
Le Roith, D.,
and Zick, Y.
(2001)
Diabetes Care
24,
588-597 |
64. |
Aguirre, V.,
Werner, E. D.,
Giraud, J.,
Lee, Y. H.,
Shoelson, S. E.,
and White, M. F.
(2002)
J. Biol. Chem.
277,
1531-1537 |
65. |
Rui, L.,
Aguirre, V.,
Kim, J. K.,
Shulman, G. I.,
Lee, A.,
Corbould, A.,
Dunaif, A.,
and White, M. F.
(2001)
J. Clin. Invest.
107,
181-189 |
66. |
Lee, Y. H.,
Giraud, J.,
Davis, R. J.,
and White, M. F.
(2003)
J. Biol. Chem.
278,
2896-2902 |
67. |
Yu, C.,
Chen, Y.,
Zong, H.,
Wang, Y.,
Bergeron, R.,
Kim, J. K.,
Cline, G. W.,
Cushman, S. W.,
Cooney, G. J.,
Atcheson, B.,
White, M. F.,
Kraegen, E. W.,
and Shulman, G. I.
(2002)
J. Biol. Chem.
277,
50230-50236 |
68. | Jiang, G., Dallas-Yang, Q., Liu, F., Moller, D. E., and Zhang, B. B. (2002) J. Biol. Chem. 278, 180-186 |
69. |
Gao, Z.,
Hwang, D.,
Bataille, F.,
Lefevre, M.,
York, D.,
Quon, M.,
and Ye, J.
(2002)
J. Biol. Chem.
277,
48115-48121 |
70. |
Peterson, R. T.,
Desai, B. N.,
Hardwick, J. S.,
and Schreiber, S. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4438-4442 |